November 27-29 2018
Cambridge, MA, USA

 

Day One
Wednesday, November 28, 2018

Day Two
Thursday, November 29, 2018

08.20
Chair’s Opening Remarks

Harnessing the Understanding of Molecular Pathology & Regenerative Medicine for the Identification of Druggable Targets

08.30
Overview of Novel Anti-Fibrotic Therapies

  • David Lagares Director of the Matrix and Mechanobiology Program, Massachusetts General Hospital

Synopsis

  • Discussing therapeutic strategies to block pathologic TGFβ signalling without affecting its homeostatic functions
  • Targeting myofibroblast apoptosis to reverse established fibrosis
  • Mechanotherapeutics: Targeting mechanical signaling pathways in fibrotic disease

09.00
Panel Discussion: Fibrosis A Cause or a Consequence?

  • Alexey Lugovsky Chief Development Officer, Morphic Therapeutics
  • David Lagares Director of the Matrix and Mechanobiology Program, Massachusetts General Hospital
  • Matthew Breyer Distinguished Scientist, Cardiovascular & Metabolism, Janssen Pharmaceuticals
  • Peter Blume-Jensen Chief Executive Officer, Acrivon Therapeutics

Synopsis

  • What are the disease driving molecular alterations and processes?
  • Can we understand and address the gap between resolution of inflammation and fibrosis to understand the therapeutic potential of reparative inflammation?
  • Are there other biological pathways to consider, such as oxidative stress, as drivers of
    fibosis?

09.30
Anti-fibrotic Therapies for the Heart

Synopsis

  • Addressing the challenges in targeting cardiac fibrosis
  • Showcasing Cardiol Therapeutic’s research

10.00
Morning Break & Poster Session

Clinical Trial Design to Better Demonstrate Clinically Meaningful Anti-Fibrotic Activity

10.30
The Importance of Patient Stratification to Fibrosis Clinical Studies

Synopsis

  • Critically reviewing patient heterogeneity in fibrosis
  • Outlining markers of heterogeneity
  • Applying understanding to clinical studies

11.00
Transforming IPF Clinical Trials Through Direct Patient Engagement

  • Komathi Stem Founder & Chief Executive Officer , monARC Bionetworks

Case Studies of Anti-Fibrotic Intervention: Targetting Disease Driving Mechanisms

11.15
Integrin Targets with Pharmacological Relevance in Inflammation & Fibrosis

Synopsis

  • Introducing and reviewing integrins in the context of therapeutic targets in fibrosis
  • Reviewing clinical precedents to date
  • Showcasing Morphic’s integrin targeting pipeline

11.45
Development of 3rd Generation Rho Kinase Inhibitors Targeting Fibrotic Diseases

  • Masha Poyurovsky Vice President, Head of Molecular Signalling, Kadmon Pharmaceuticals

Synopsis

  • Outlining the central role of ROCK in biomechanical and biochemical signalling pathways
  • Sharing challenges and lessons learnt from initial ROCK inhibitor discovery programs
  • Showcasing the next generation ROCK inhibitors: safety and efficacy in fibrosis models

12.15
Lunch & Networking

Case Studies: Mechanisms of Action & New Targets in Fibrosis

13.30
Reducing Fibrosis by Inhibiting Lysyl Oxidases

Synopsis

  • Demonstrating inhibition of lysl oxidases in the reduction of fibrosis and cancer progression
  • Reviewing this therapeutic approach by analyzing selective lysyl oxidase entering the
    clinic

14.00
Physiological Control Systems Involving Galectins in Treatment of Diseases

Synopsis

  • Highlighting galectins as a family of highly conserved molecular effectors that mediate various biological processes
  • Analyzing therapeutic discovery and development for clinical intervention against fibrosis, cancer, and other disorders involving galectins
  • Reviewing the role of galectins in mediating physiological control processes including an understanding of structure-function relationships, mechanisms of action at the molecular level and evolving clinical data on their role in the treatment of various diseases

14.30
Afternoon Break & Networking

15.00
Stem Cell Factor: A Critical Activating Mechanism in Tissue Remodeling

Synopsis

  • Debating SCF as necessary for c-kit positive immune cell recruitment and activation in fibrosis
  • Proving targeting the fibroblast isoform of SCF with a monoclonal antibody, OpSCF, is effective therapy in many preclinical models of remodeling and fibrosis
  • Showcasing OpSCF as humanized and development-ready

15.30
Wnt Pathway Suppression & Fibrosis

Synopsis

  • Outlining the role of wnt protein upregulation in fibrosis and tissue remodelling, and demonstrating how wnt suppression has been shown to be an effective method of ameliorating fibrosis in several animal models
  • Validating porcupine inhibitors as suppressors of wnt signalling
  • Showcasing RedX’s novel and potent porcupine inhibitor as a suppressor of fibrosis
    development and therapeutic potential in IPF

16.00
Chair’s Closing Remarks